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ABSTRACT: The Stabilin receptors are systemic clearance receptors for some classes of chemically modiﬁed
nucleic acid therapeutics. In this study, the recombinant
human secreted ecto-domain of the small isoform of
Stabilin-2 (s190) was puriﬁed from cell culture and
evaluated for direct binding with a multitude of antisense
oligonucleotides (ASOs) using a ﬂuorescence polarizationbased assay. The tested ASOs varied in their backbone
composition, modiﬁcation of the ribose 2′ position, overall
length of the oligo, and sequence of the nucleotide bases.
A fully phosphorothioate (PS) ASO with a 5−10−5
pattern of ﬂanking 2′-O-methoxyethyl modiﬁcations was
then used to test the eﬀects of pH and salt concentration
on receptor binding. These tests concluded that the PS
backbone was the primary determinant for ASO binding
and that decreasing pH and increasing salt generally
increased the rate of ligand dissociation and ﬁt within the
biological parameters expected of a constitutive recycling
receptor. These results will be useful in the rational design
of therapeutic oligonucleotides for enhancing their aﬃnity
or avoidance of the Stabilin receptors.

Figure 1. Structures of chemical modiﬁcations used in this study.

cleotides (PS-ASOs).8 Both human Stabilin-1 and Stabilin-2 are
∼315 kDa type 1 receptors with a single transmembrane
domain and a short cytoplasmic tail.9 Stabilin-1 is more widely
expressed within endothelial cells and alternatively activated
macrophages.10 Stabilin-2 is expressed at a high level in the
liver, spleen, bone marrow, and lymph node sinusoidal
endothelium and at a lower level in speciﬁc tissues within the
muscle, brain, and kidney.11−13 Both receptors share the same
domain organization in which the extracellular portion consists
of seven Fasciclin-1 domains separated by four clusters
consisting of four to six EGF/EGF-like domains, and an XLink domain that binds hyaluronan in Stabilin-2 but is
dysfunctional in Stabilin-1.14 Both receptors bind with ligands
such as heparin,15 PS-ASOs,8 phosphatidylserine,16,17 and
oxidized low-density lipoprotein.18 Each protein can also
internalize their own unique ligands such as SPARC19 and
placental lactogen20 for Stabilin-1 and hyaluronan21 and
chondroitin sulfates A, C, and D for Stabilin-2.22 Sodium
dodecyl sulfate−polyacrylamide gel electrophoresis analysis of
the receptor demonstrates that Stabilin-1 is expressed as two
high-molecular weight proteins (1:1 ratio) that migrate as a
tight doublet in contrast to Stabilin-2, which is expressed as 315
and 190 kDa isoforms in an approximately 1:1 ratio in native
tissues.23 For the experiments outlined in this report, we
utilized the ecto-domain of the recombinant 190 kDa isoform
(s190) of Stabilin-2 as it has a high level of expression and/or
secretion in cell lines and may be puriﬁed to near 100% purity

A

ntisense oligonucleotides (ASOs) are short (14−25)
chemically modiﬁed nucleic acids that have made rapid
progress for the treatment of congenital and acquired metabolic
diseases.1 The eﬀectiveness of an ASO relies on several
parameters, including biological stability, adherence to cellsurface proteins, internalization within the cells, and escape
from endosomes and speciﬁcity to the target RNA.2,3 To
increase their stability in biological ﬂuids, they are often
designed with a phosphorothioate linkage in which the free
nonbridging oxygen atom of the phosphodiester backbone is
replaced with a sulfur atom, rendering the polymer resistant to
nucleases.4 The PS backbone also enhances the avidity of ASO
for plasma and cell-surface proteins that promote distribution
to tissues and cellular accumulation.5 Gen 2 ASOs typically
have the gapmer design in which a central region of DNA
nucleotides is ﬂanked by 2′-modiﬁed nucleotide analogues that
further enhance nuclease stability and RNA binding aﬃnity.6
Commonly used 2′-modiﬁed analogues used in gapmers
include 2′-methoxyethyl RNA (MOE), constrained ethyl
BNA (cEt), and locked nucleic acid (LNA)7 (Figure 1).
Our collaborative group discovered that the Stabilin class of
receptors, of which there are two members, is responsible for
the systemic clearance of phosphorothioate antisense oligonu© 2018 American Chemical Society
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using aﬃnity chromatography. Both isoforms have the same
activity against PS-ASOs.8
Previously, we used the recombinant 190 kDa isoform
expressed in cell lines and the s190 puriﬁed protein to assess
PS-ASO binding and internalization. From both enzyme-linked
immunosorbent assay (ELISA)-like assays and internalization
data with [125I]PS-ASO (5−10−5 oligo), we determined that
the binding aﬃnity was ∼140 nM.8 Competition assays were
utilized to determine the eﬀect of chemical modiﬁcations and
oligonucleotide composition on Stab2 binding. The competition assays did not accurately inform the direct binding of the
competitors or their lower aﬃnity for the receptor. The
objective in this report was to assess direct binding of a variety
of ASOs to determine which chemistries (Figure 1) provide the
weaker and stronger interaction between the nucleic acid and
s190 using a sensitive ﬂuorescence polarization (FP) assay.24,25
A series of experiments were performed using diﬀerent
variants of an ASO targeting phosphatase and tensin
homologue (PTEN) mRNA to determine their aﬃnity for
s190. The interaction between the protein receptor and PTEN
ASO was then challenged by pH and salt dependence.
Table 1 (Figure 2A) provides a summary of results for the
initial binding experiments with the PTEN ASOs. It was found

Figure 2. Direct ASO binding to s190 (Stab2). (A) PTEN ASOs with
various chemistries. (B) ASOs with diﬀering sequences and designs.

Table 2. Eﬀect of Sequence and Design on Binding to s190
(Stab2)a

Table 1. Binding of PTEN ASOs to s190 (Stab2)a

a

Orange letters indicate MOE and black letters DNA. N indicates a
PS-modiﬁed abasic oligonucleotide, and X = Alexa 647 Fluor.

a

Orange letters indicate MOE, gray letters RNA, black letters DNA,
green letters 2′F RNA, and blue letters cEt modiﬁcations. All
oligonucleotides are PS-modiﬁed, except for underlined letters, which
are natural phosphodiesters (PO). Oligos with a mixture of PS and PO
linkages are mixed backbone (MBB); X = Alexa 647 Fluor. The
number in parentheses is a value from duplicate measurements.

and, therefore, has a lower binding aﬃnity. Rigidity may also be
the reason for which the double-stranded PTEN ASO has an
aﬃnity lower than that of the single-stranded ASO in Table 1.
The tight binding with the A-basic ASO (ASO 16) conﬁrms
that the PS modiﬁcation is the binding motif for Stabilin-2,
which is in agreement with the PTEN ASOs in which the PO
version of the PTEN ASO does not bind with s190.
The eﬀect of pH on ASO binding is important to examine as
once the receptor is internalized in early endosomes, the pH
decreases during endosomal maturation. Using a mixture of
mono- and divalent 10 mM sodium phosphate buﬀers
containing 150 mM NaCl, the ﬂuorescence-based assay was
repeated under four pH conditions (Figure 3A). As the pH
decreased from 7.4 to 5.0, the aﬃnity decreased. For most
protein−ASO interactions that have been observed thus far, the
opposite trend or no change in binding aﬃnity is the typical
result. In other proteins and receptors, the higher aﬃnity at
lower pH may be the result of a more positive charge that is
attractive to the polyanionic PS ASO.26 However, this is clearly
not the case with this receptor. Most, if not all, professional
endocytic receptors release their cargo under low-pH (<5.5)
conditions,27 and this may be the reason for the results
observed for Stabilin-2.

that the receptor has a signiﬁcantly higher aﬃnity for singlestranded ASO (ASO 1) than for double-stranded molecules in
which the same ASO was bound with a RNA complement
(ASO 8). The phosphorothioate linkage is highly preferred for
binding (ASO 1) in contrast to the phosphodiester oligo (ASO
5), and the aﬃnity rapidly drops as the oligo length is reduced
to 15 bases (ASO 6) and 10 bases (ASO 7). The ﬁve ﬂanking
bases with 2′ modiﬁcations did not aﬀect the overall aﬃnity,
indicating that the PS modiﬁcation on the oligo backbone is the
primary contributor for Stabilin-2 binding (compare ASO 5
with ASO 1, 9, and 10).
The same experiments were repeated using a “gapmer”
designed set of oligos (Figure 2B and Table 2). The control for
this group is PTEN ASO 1. All of these PS-based oligos (ASO
11−15) bound with aﬃnities within 1 order of magnitude of
each other (15−73 nM). The T20 (ASO 17) and A20 (ASO 18)
oligos were also compared against each other, which resulted in
A20 having a 20-fold weaker aﬃnity for the receptor. The
explanation for this observation is the assumption that because
of the helical self-stacking of the purine bases, A20 is more rigid
2062
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Previous experiments with an ELISA type assay revealed that
PS ASO−protein binding is dependent on ionic bonding.8 We
repeated this assay with the FP method and found that, as
before, the aﬃnity of the ASO for the receptor decreases as the
ionic strength increases (Figure 3B). It is somewhat surprising
that binding aﬃnity is weakest at the lowest salt concentration
and may be a result of an artifact from the experimental method
or that low concentrations of salt perturb protein structure
enough to decrease the level of ASO binding. Any perturbation
to salt concentration may alter the physical and chemical
environment of the binding site(s). There are no structural data
for this receptor, and the s190 used in these experiments
contains 1359 amino acids, including 104 cysteine residues;
thus, predicting overall and speciﬁc subdomain structures is not
possible at this time (Figure S1).
This ﬂuorescence-based assay conﬁrmed the results from our
previous report describing the high aﬃnity of the PS-based
ASO for the Stabilin receptors.8 This is the ﬁrst report in which
direct binding aﬃnities have been observed with a multitude of
diﬀerent PS and non-PS ASOs that could not have been
attained otherwise. With this information, it is clear that the
length of the PS backbone and the single-stranded nature of the
nucleic acid are the primary determinants for binding to the
Stabilin receptors. In addition, the nucleotide sequence does
not substantially aﬀect the aﬃnity for the receptor.
The sequence-independent tissue accumulation properties of
PS ASOs in the liver have been used advantageously for the
clinical development of ASO therapeutics. Our binding data
show that PS ASOs can bind the Stabilin receptors, and
presumably other cell-surface proteins, in a PS-dependent but
sequence-independent manner and provide a rationale for the
predictable liver accumulation properties of single-stranded PS
ASOs in animals. Our data also emphasize the importance of
interactions with cell-surface proteins for the promotion of
cellular internalization of nucleic acid-based therapeutics.
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Purification of the soluble 190-HARE ecto-domain (s190)
A stable cell line expressing the s190 ecto-domain was previously developed and
described in Harris et al1. Cells were cultured in 4-chamber Celldisc flasks (Greiner-bio One) at
37°C, 5% CO2. The s190 protein is secreted from the cells in growth medium containing DMEM
supplemented with 8% fetal bovine serum and 50 µg/mL hygromycin B. A batch of 500 mL of
condition medium was incubated with 1 mL of packed mAb30 resin. Monoclonal antibody 30
(mAb30) is a monoclonal antibody against rat HARE (175-kDa) isoform that also reacts against
the human receptor2. The antibody was conjugated with cyanogen-bromide activated sepharose
(#C9142, SigmaAldrich) according to the manufacturer’s instructions. Both resin and
conditioned medium were rotated slowly overnight at 4°C and the resin was separated from the
medium using a single gravity flow column (#9704352, BioRad, Hercules, CA, USA). Excess
protein and media were washed from the resin using 10 bed volumes of saline (500 mM NaCl,
20 mM sodium phosphate monobasic, pH 7.2). s190 protein was eluted from the resin using four
sequential bed volumes of 100 mM glycine, pH 3 which dripped into a 15 mL conical containing
4 bed volumes of 1 M unbuffered Tris buffer, pH 11. The resin was immediately rinsed with
saline (150 mM NaCl, pH 7.2) and stored at 4°C for re-use. The eluted protein was concentrated
and buffered exchanged with 1X PBS (150 mM NaCl, 20 mM sodium phosphate monobasic)
using Vivaspin Turbo 4 concentrators (#VS04T41, MWCO = 100,000, Sartorius) down to a
volume of 0.3-0.5 mL and quantified by the Bicinchoninic (BCA) assay (BioRad, Hercules, CA,
USA).
Fluorescence polarization assay
Fluorescence polarization experiments were performed using ALEXA647-labeled ASOs
synthesized at Integrated DNA Technologies (Coralville, IA, USA). Measurements were
performed in 1X phosphate buffered saline (PBS), except for the experiments to determine salt
and pH dependence of binding. For those evaluations a 10 mM phosphate buffer with a sodium
chloride concentration of 50 to 200 mM and a pH of 5, 6, or 7 was utilized. The assay was set up
in 96-well costar plates (black flat-bottomed non-binding) purchased from Corning, NY, USA.
Binding was evaluated by adding ALEXA647-labeled ASOs to yield 2 nM concentration to each
well containing 100 µL of Stabilin-2 protein from sub nM to low µM concentration. Readings
were taken using the Tecan (Baldwin Park, CA, USA) InfiniteM1000 Pro instrument (λex =635
nm, λem =675 nm). Using polarized excitation and emission filters, the instrument measures
fluorescence perpendicular to the excitation plane (the ’P-channel’) and fluorescence that is
parallel to the excitation plane (the ‘S-channel’), and then it calculates FP in millipolarization
units (mP) as follows: mP = [(S – P * G) / (S + P * G)] * 1000. The ‘G-factor’ is measured by
the instrument as a correction for any bias toward the P channel 3. Polarization values of each
ALEXA647-labeled ASO in 1X PBS at 2 nM concentration were subtracted from each
measurement. Kd values were calculated with GraphPad Prism 5 software (GraphPad Software,
La Jolla, CA, USA) using non-linear regression for curve fit assuming one binding site.

S2

Fig. S1: Amino acid sequence of the s190 ectodomain of Stabilin-2 that was purified and used in the
fluorescence polarization assay. Color coding is indicated below.
TKLALFESLPNLLMRLEQMPDYPIFRGYIIQYNLANAIEAADAYTVFAPNNNAIENYIREKKVLSLEEDV
LRYHVVLEEKLLKNDLHNGMHRETMLGFSYFLSFFLHNDQLYVNEAPINYTNVATDKGVIHGLGKVLEIQ
KNRCDNNATTIIRGRCRTCSSELTCPFGTKSLGNEKRRCIYTSYFMGRRTLFIGCQPKCVRTVITRECCA
GFFGPQCQPCPGNAQNVCFGNGICLDGVNGTGVCECGEGFSGTACETCTEGKYGIHCDQACSCVHGRCNQ
GPLGDGSCDCDVGWRGVHCDNATTEDNCNGTCHTSANCLTNSDGTASCKCAAGFQGNGTICTAINACEIS
NGGCSAKADCKRTTPGRRVCTCKAGYTGDGIVCLEINPCLENHGGCDKNAECTQTGPNQAACNCLPAYTG
DGKVCTLINVCLTKNGGCSEFAICNHTGQVERTCTCKPNYIGDGFTCRGSIYQELPKNPKTSQYFFQLQE
HFVKDLVGPGPFTVFAPLSAAFDEEARVKDWDKYGLMPQVLRYHVVACHQLLLENLKLISNATSLQGEPI
VISVSQSTVYINNKAKIISSDIISTNGIVHIIDKLLSPKNLLITPKDNSGRILQNLTTLATNNGYIKFSN
LIQDSGLLSVITDPIHTPVTLFWPTDQALHALPAEQQDFLFNQDNKDKLKEYLKFHVIRDAKVLAVDLPT
STAWKTLQGSELSVKCGAGRDIGDLFLNGQTCRIVQRELLFDLGVAYGIDCLLIDPTLGGRCDTFTTFDA
SGECGSCVNTPSCPRWSKPKGVKQKCLYNLPFKRNLEGCRERCSLVIQIPRCCKGYFGRDCQACPGGPDA
PCNNRGVCLDQYSATGECKCNTGFNGTACEMCWPGRFGPDCLPCGCSDHGQCDDGITGSGQCLCETGWTG
PSCDTQAVLPAVCTPPCSAHATCKENNTCECNLDYEGDGITCTVVDFCKQDNGGCAKVARCSQKGTKVSC
SCQKGYKGDGHSCTEIDPCADGLNGGCHEHATCKMTGPGKHKCECKSHYVGDGLNCEPEQLPIDRCLQDN
GQCHADAKCVDLHFQDTTVGVFHLRSPLGQYKLTFDKAREACANEAATMATYNQLSYAQKAKYHLCSAGW
LETGRVAYPTAFASQNCGSGVVGIVDYGPRPNKSEMWDVFCYRMKDVNCTCKVGYVGDGFSCSGNLLQVL
MSFPSLTNFLTEVLAYSNSSARGRAFLEHLTDLSIRGTLFVPQNSGLGENETLSGRDIEHHLANVSMFFY
NDLVNGTTLQTRLGSKLLITASQDPLQPTETRFVDGRAILQWDIFASNGIIHVISRPLKAPPAPVKGELG
TELGSEGKPIPNPLLGLDSTRTGHHHHHH
Remnant of the signal sequence from vector plasmid
S190 HARE ectodomain
EGF/EGF-like domains
Fasciclin-1 domains
Link domain
Remnant of the original vector MCS sequence
V5 epitope tag
6xHis tag
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